Anti-nociceptive and sedative effects of XXXX , @entity1340 and their combination administered intravenously slowly in ponies.

@entity6226 @entity1340 @entity299 @entity138
OBJECTIVE: To evaluate the anti-nociceptive and sedative effects of slow intravenous (IV) injection of @entity1340 , @entity6226 , or a combination of both drugs in ponies. STUDY DESIGN: Within-subject blinded. ANIMALS: Twenty ponies (seven male, 13 female, weighing mean      SD 268.0      128  kg). METHODS: On separate occasions, each pony received one of the following three treatments IV; @entity6226 50   g  kg(-) (R) @entity1340 3  mg  kg(-1) given over 15  minutes (T) or @entity1340 3  mg  kg(-1) followed by @entity6226 50   g  kg(-1) ( @entity138 ). Physiologic parameters and caecal borborygmi (CB) were measured and sedation and response to electrical stimulation of the coronary band assessed before and up to 120  minutes following drugs administration. Results were analyzed using the Friedman's test and 2 way anova as relevant. RESULTS: When compared to baseline, @entity299 ( @entity299 , beats minute(-1) ) and respiratory rates (fR , breaths minute(-1) ) increased with treatment T (highest mean      SD, @entity299 43      1; fR 33      2) and decreased with R (lowest @entity299 29      1 and fR 10      4) and @entity138 (lowest @entity299 32      1 and fR 9      3). There were no changes in other measured physiological variables. The height of head from the ground was lower following treatments R and TR than T. There was slight ataxia with all three treatments. No excitatory behavioural effects were observed. The response to electrical stimulation was reduced for a prolonged period relative to baseline following all three treatments, the effect being significantly greatest with treatment @entity138 . CONCLUSION: @entity1340 combined with @entity6226 at the stated doses proved an effective sedative and anti-nociceptive combination in ponies, with no unacceptable behavioural or physiologic side effects. CLINICAL RELEVANCE: Slow controlled administration of @entity1340 should reduce the occurrence of adverse behavioural side effects.
